Bristol Myers Squibb Company $BMY Shares Sold by MRA Advisory Group

MRA Advisory Group lessened its position in Bristol Myers Squibb Company (NYSE:BMY) by 76.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,646 shares of the biopharmaceutical company’s stock after selling 18,006 shares during the period. MRA Advisory Group’s holdings in Bristol Myers Squibb were worth $352,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Primecap Management Co. CA bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $1,436,115,000. Legal & General Group Plc bought a new position in Bristol Myers Squibb during the second quarter worth about $980,862,000. BlackRock Inc. grew its stake in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. State Street Corp grew its stake in Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares during the period. Finally, SG Americas Securities LLC increased its holdings in shares of Bristol Myers Squibb by 153.8% in the first quarter. SG Americas Securities LLC now owns 8,910,032 shares of the biopharmaceutical company’s stock worth $540,393,000 after acquiring an additional 5,399,407 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Stock Up 0.3%

BMY traded up $0.17 on Wednesday, hitting $59.77. 5,291,411 shares of the company were exchanged, compared to its average volume of 11,979,384. The stock’s fifty day moving average is $64.45 and its 200-day moving average is $60.26. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company has a market cap of $122.08 billion, a PE ratio of 13.14, a PEG ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the previous year, the firm earned $1.46 EPS. The business’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Wall Street Analyst Weigh In

BMY has been the topic of several recent analyst reports. Roth Capital started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $63.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, September 23rd. Guggenheim reaffirmed a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Bank of America reduced their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Finally, Raymond James Financial initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.06.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.